Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 233 results

Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)

PAR
Wednesday, September 8, 2021
Tuesday, December 12, 2023
K43
PAR-21-252

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-. The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups , including low-income, lower-middle-income, and upper-middle-income countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

Emerging Global Leader Award (K43 Independent Clinical Trial Required)

PAR
Wednesday, September 8, 2021
Tuesday, December 12, 2023
K43
PAR-21-251

Funding Opportunity Purpose

This is a reissue of the Emerging Global Leader Program (K43) to align with the clinical trials policy.

Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)

PAR
Thursday, September 2, 2021
Friday, October 22, 2021
R01
PAR-22-029

Funding Opportunity Purpose

This FOA aims to address three major goals. The first is to utilize single-cell(-nuc) technologies to characterize the changes to cell identity, number, and/or morphology within a defined brain region, the hippocampus, from subjects experiencing mild cognitive impairment (MCI). Specifically, applicants will collect single-cell(-nuc) transcriptomic and epigenetic data from neuronal, glial, or vascular cells using MCI autopsy brains. Next, applicants will propose a data coordination center to collect single-cell(-nuc) omics data generated using diverse tissue sources and various, well-documented tissue preparation techniques from each group in the consortium. This data will be used to identify critical factors for robust and accurate single-cell(-nuc) omics analysis. Finally, this FOA will prompt applicants to coordinate their single-cell(-nuc) data sets with those produced by the BRAIN Initiatives human cell census. The aim is to enable investigators to utilize BRAIN cell census data sets generated from the analysis of healthy human brain and harmonize single-cell(-nuc) data sets from ADRD human brains with the BRAIN Initiative cell type registry.

NINDS Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)

PAR
Thursday, September 2, 2021
Saturday, July 13, 2024
K99/R00
PAR-22-022

Funding Opportunity Purpose

The purpose of the NINDS Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support of a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research. The program is designed to facilitate a timely transition of promising postdoctoral researchers from diverse backgrounds (e.g., see NIHs Interest in Diversity) from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field. This FOA is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.

HEAL Initiative: Interdisciplinary Teams to Elucidate the Mechanisms of Device-Based Pain Relief (RM1 Clinical Trial Optional)

RFA
Tuesday, August 31, 2021
Thursday, November 4, 2021
RFA-NS-22-016

Funding Opportunity Purpose

More than 25 million Americans suffer from daily chronic pain, a highly debilitating medical condition that is complex and difficult to manage. In recent decades, there has been an overreliance in the prescription of opioids for chronic pain despite their poor ability to improve function and high addiction liability. This contributed to a significant and alarming epidemic of opioid overdose deaths and addictions. Innovative scientific solutions to develop alternative pain treatment options are thus critically needed. Through targeted research efforts, the NIH HEAL Initiative aims to support the development of safe and effective devices to treat pain with little or no addiction liability. This funding opportunity announcement (FOA) is designed to support interdisciplinary research teams of multiple PD/PIs to investigate the mechanism of action of device-based pain relief with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. Program teams are expected to accomplish goals that require considerable synergy and collaborative interactions. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider objectives that will produce major advances in the field of device-based pain relief.

Limited Competition: Knockout Mouse Phenotyping Project Data Coordination Center and Database (UM1 Clinical Trial Not Allowed)

RFA
Tuesday, August 31, 2021
Tuesday, November 2, 2021
RFA-HG-21-037

Funding Opportunity Purpose

The purpose of the Knockout Mouse Phenotyping Project (KOMP2) is to produce a comprehensive resource of null-mutant mice, and associated phenotype data, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. The goal of this FOA is to provide informatics support to NIH funded projects that are performing high-throughput broad-based phenotyping of mouse knock-out (KO) lines (see RFA-HG-21-036) and to coordinate with international efforts so as to integrate all data into a common database under the auspices of the International Mouse Phenotyping Consortium (IMPC). The Data Coordination Center and Database (DCCDB) will perform the validation, analysis, annotation, visualization, and dissemination of the phenotype data from the knockout lines. Curation will require integration with other data sources. This is a limited competition RFA. Only recipient organizations funded under (RFA-RM-15-016) are eligible to apply.

Limited Competition: Knockout Mouse Production and Phenotyping Project (UM1) Clinical Trial Not Allowed

RFA
Tuesday, August 31, 2021
Tuesday, November 2, 2021
RFA-HG-21-036

Funding Opportunity Purpose

The purpose of the Knockout Mouse Phenotyping Project (KOMP2) is to produce a comprehensive resource of null-mutant mice, and associated phenotype data, for the purpose of elucidating functional information for each protein-coding gene in the mammalian genome. This Funding Opportunity Announcement (FOA) solicits applications for production and phenotyping centers that will make maximum progress toward completion of KOMP2 in a final five-year project period. The specific objectives are to generate approximately 1,200 mutant mouse lines using CRISPR/Cas9 technology, perform a series of phenotyping assays, cryopreserve germplasm, and make mice and data readily available to the research community. This is a limited competition RFA. Only recipient organizations funded under (RFA-RM-15-017) are eligible to apply.

Notice of Special Interest to Encourage Eligible NIH BRAIN Initiative Awardees to Apply for PA-21-071 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Notice of Special Interest
Thursday, August 26, 2021
Monday, September 30, 2024
333
NOT-NS-22-012

Funding Opportunity Purpose

This Notice encourages eligible awardees in the BRAIN Initiative community to apply for administrative supplements in response to PA-21-071, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). The NIH has a strong interest in the diversity of the NIH-funded workforce (see NOT-OD-18-210) and encourages institutions to diversify their populations by enhancing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences.

HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Advance the Study of Chronic Overlapping Pain Conditions (COPCs)

Notice of Special Interest
Wednesday, August 25, 2021
Saturday, November 6, 2021
333
NOT-NS-21-068

Funding Opportunity Purpose

The purpose of this request for administrative supplements to current NIH-fundedstudies is to encourage clinical and translational research that will increase our understanding of the prevalence, psychological variables, and response to therapy in those individuals with multiple chronic overlapping pain conditions (COPCs). Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one pain disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the characteristics of overlapping pain conditions, the progression of these conditions, and therapeutic approaches best suited for treating individuals with COPCs. Research efforts in chronic pain conditions have focused on single disorders or types of pain such as neuropathic and inflammatory pain. These research efforts have generated a substantial body of information advancing our understanding of the underlying mechanisms of pain onset and development, the transition from acute to chronic pain, and therapeutic targets for treating acute and chronic pain. Over the past twenty years reports have documented the presence of more than one chronic pain condition in subjects with pain. Studies have identified overlap between a number of chronic pain conditions, including lower back pain, fibromyalgia (FM), vulvodynia, endometriosis, functional gastrointestinal disorders such as irritable bowel syndrome (IBS), temporomandibular joint disorder (TMD), migraine, tension headache, low back pain, and urologic chronic pelvic pain syndromes (UCPPS). These results suggest that chronic pain conditions may not be localized conditions but may share symptoms and mechanisms that involve a general central nervous system dysfunction as well as disorder-specific symptoms.

Autism Centers of Excellence: Centers (P50 Clinical Trial Optional)

RFA
Monday, August 23, 2021
Wednesday, November 10, 2021
P50
RFA-HD-22-008

Funding Opportunity Purpose

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and partnering Institutes invite applications for the Autism Centers of Excellence: Centers Program, hereafter termed ACE Centers. The P50 mechanism allows for integrative, multi-disciplinary, coordinated programs of research that demonstrate cohesion and synergy across research projects and cores. A companion FOA (RFA-HD-22-007) invites applications for ACE Networks supported by the R01 mechanism.

Pages